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Introduction
Recombinant adenoviruses are promising vectors for gene transfer to lung, liver and other tissues. For example, they have been used to express CFTR in human airway cells in vitro, in the airways of animals in vivo, and in the airways of humans with CF (see Refs 1-3 for review). They have also been used to express several proteins in liver after intravenous injection in animals. 4, 5 Because adenovirus is not an integrating virus, some applications will require repeated administration. However, with repeated administration, both animals and humans develop an immune response that limits gene expression with subsequent vector administration. The immune response can have two components, cellmediated and humoral immunity. The cell-mediated response is generated primarily when infected cells produce low levels of adenoviral proteins. 6, 7 Cell-mediated immunity destroys infected cells that express viral protein, thereby limiting production of transgene with repeated administration. The humoral immune response is generated by administration of adenoviral proteins with the subsequent production of anti-adenoviral antibodies. [7] [8] [9] [10] [11] [12] Some antibodies inactivate the virus (neutralizing antibodies) by binding to capsid proteins that are required for binding virus to cells, for internaliz-ation, for escape from endosomes, and for delivery of viral DNA to the nucleus. 13 Several studies have shown the importance of neutralizing antibodies in preventing infection and gene transfer. For example, when virus is delivered multiple times to lung, neutralizing antibodies develop that block subsequent infection. [7] [8] [9] [10] [11] Moreover, we found an increase in the titer of neutralizing antibodies after four and five adenovirus administrations to airway epithelia in humans. 14 Solutions to these problems will be required if adenoviral vectors are to be used for repeat administration or for administration to people who have developed wild-type infections and have preexisting neutralizing antibodies.
Several previous attempts to circumvent the humoral and cellular immune responses have focused on suppressing the host immune system. [15] [16] [17] This approach has the potential advantage that it could suppress both arms of the immune system. However, immune suppression can have disadvantages. A more specific strategy to abrogate cell-mediated immunity is to delete several or all of the viral genes from the vector; this could prevent infected cells from producing new viral proteins.
18-20 This approach shows significant promise for minimizing or abolishing the cell-mediated immune response. However, such a strategy will not eliminate the development of neutralizing antibodies because viral proteins will still be delivered to the recipient.
One way to protect virus from neutralizing antibody would be to coat it with a substance that would shield viral proteins. However coating vector with a protective substance could also prevent capsid proteins from binding to the cell surface and initiating infection. Thus, if the virus were enveloped, the coating substance would need to provide a means for binding to the cell surface. We recently reported that cationic molecules could bind to and increase the efficiency of gene transfer in vitro and in vivo to cells and tissues that are relatively resistant to adenovirus infection. 21 Efficiency was improved when the vector was complexed with cationic lipids, poly-llysine (PLL) and several other compounds. The greatest benefit occurred in cells and tissues that are relatively resistant to adenovirus infection. The data suggested: that binding was dependent on an electrostatic interaction with the cell surface; that entry did not require an interaction of adenovirus fiber protein with the cell surface; and that complexes entered cells via a pathway different from that utilized by adenovirus alone. In addition, electron photomicrographs suggested that the polycations might coat the viral surface.
The goal of this study was to test the hypothesis that coating the adenovirus particle would shield it from neutralizing antibody. We thought that PEG would be a valuable reagent because it has been used to modify many natural and synthetic macromolecules. PEG modification can decrease reactivity with antibody and other serum proteins without destroying enzymatic activity. [22] [23] [24] When PEG is coupled to liposomes, nanoparticles and proteins, their circulating lifetime increases, the interaction with antibodies decreases, and uptake by the reticuloendothelial system decreases. 25, 26 The amphipathic nature of PEG and its ability to induce cell fusion 27 suggested that it might provide an additional benefit by enhancing infection. We considered direct coupling of PEG to virus to coat and protect it. Although direct coupling of PEG to the vector by chemical modification could coat and protect the virus, chemical modification significantly decreased infection (Ref. 28 and unpublished observations). Therefore, we used a cationic lipid to couple PEG to the virus noncovalently. The cationic lipid could also serve another important purpose; it could bind the complex to the negatively-charged cell surface.
Results
Complexes containing adenovirus, a cationic lipid and PEG are protected from immune plasma We formed complexes using the cationic lipid GL-67, as we have previously described. 21 To incorporate PEG, we used DOPE-PEG because our earlier work showed that complexes containing GL-67/DOPE are nearly as effective for gene transfer as complexes containing only GL-67. We first optimized the ratio of GL-67 to DOPE-PEG (not shown) and then infected HeLa cells. We used HeLa cells because they are readily infected by adenovirus and therefore we could test the effect of immune plasma on transgene expression. The bottom portion of Figure 1 shows that immune plasma (1:100) inhibited expression from Ad2/␤Gal-2 alone by approximately 40-fold. The top portion of Figure 1 shows that as we increased the amount of GL-67/DOPE-PEG in complexes, the relative protection from neutralizing antibodies increased. Maximum protection was achieved at a ratio of approximately 40-80 g total lipid complexed at a 1/1 (w/w) ratio GL-67/DOPE-PEG per 10 10 viral particles. In contrast, when we complexed adenovirus with GL-67 or GL-67/DOPE (middle portions of Figure 1 ) or PLL (not shown) we found little protection from neutralizing antibodies. We tested other phosphatidylethanolamine-PEG analogs at a range of Ad:lipid ratios, including dimyristoyl, dipalmitoyl, distearoyl, and 1-palmitoyl-2-oleoyl and compared PEG of 2000 and 5000 Da. None of these were substantially better than DOPE-PEG with 5000 Da PEG at protection from neutralizing antibody or at gene transfer.
We also repeated these experiments using NIH 3T3 cells, which are not readily infected by adenovirus because they have few adenovirus fiber receptors (Refs 21 and 29, and unpublished observations). In 3T3 cells, complexes containing GL-67, GL-67/DOPE or GL-67/DOPE-PEG increased gene transfer approximately 100-fold compared with adenovirus alone (see below). However, as observed in HeLa cells, only complexes containing PEG provided protection from immune plasma.
We examined the effect of increasing amounts of immune plasma, to learn the extent to which GL-67/DOPE-PEG could protect adenovirus. Figure 2 shows that as the amount of immune plasma increased, transgene expression from Ad2/␤Gal-2 decreased; 50% neutralization occurred with approximately a 1:500 dilution. Adenovirus complexed with GL-67/DOPE-PEG was also neutralized, however higher concentrations of immune plasma were required; 50% neutralization occurred with approximately a 1:10 dilution. These data indicate that the complex affords some, but not complete protection from neutralizing antibody.
To examine further the role of the individual components (adenovirus, GL-67 and DOPE-PEG) in the complex, we prepared complexes by combining adenovirus with the following components: GL-67 resuspended alone, a formulation of GL-67 with DOPE-PEG (1:1 w/w), DOPE-PEG alone, or GL-67 and DOPE-PEG that had been resuspended separately then added together to the adenoviral particles ( Figure 3 ). In the absence of the cationic GL-67, the negatively-charged DOPE-PEG did not likely bind to the adenovirus and did not protect from neutralization. When GL-67 and DOPE-PEG components were present, but not mixed, dried down and resuspended together before complexing with adenovirus, immune plasma inhibited gene transfer. Only preparations in which GL-67 and DOPE-PEG were formulated together (GL-67/DOPE-PEG) afforded protection from immune plasma. Although we cannot exclude the possibility that PEG may have changed the configuration of the components, these results suggest that resistance to immune plasma requires incorporation of PEG in the complex.
Figure 3 Expression induced by adenovirus:GL-67/DOPE-PEG complexes versus that induced by addition of individual components. Transgene expression was measured after treatment of 3T3 cells with: adenovirus alone (Ad); adenovirus complexed with GL-67 (Ad:GL-67); adenovirus complexed with GL-67/DOPE-PEG (Ad:GL-67/DOPE-PEG); adenovirus mixed with DOPE-PEG alone (Ad:DOPE-PEG); and adenovirus complexed with separately added GL-67 and DOPE-PEG (Ad + GL-67 + DOPE-PEG

Complexes protect the virus from interaction with antibody
The expression data suggest that GL-67/DOPE-PEG prevented antibody from interacting with the virus. To evaluate this further, we asked whether gold-labeled anti-hexon antibodies would bind to virus in complexes. Many of these gold particles associated with adenovirus alone ( Figure 4A ) and with adenovirus coated with GL-67 ( Figure 4B ). But few associated with adenovirus in complexes with GL-67/DOPE-PEG ( Figure 4C ). These results suggest that GL-67/DOPE-PEG coated the virus, shielding it from the antibody. Because complexes that contained GL-67/DOPE-PEG did not adhere well to microscopy grid, we were able to observe only a few complexes. Therefore, we also evaluated binding by incubating complexes with antiadenovirus antibodies bound to magnetic beads. The virus was then immunoprecipitated with the beads and probed by hybridization. Figure 4E shows that less of the complex of Ad:GL-67/DOPE-PEG was immunoprecipitated than adenovirus alone. These results support the data obtained from electron microscopy and indicate that GL-67/DOPE-PEG forms a protective barrier that prevents the interaction between antibody and virus.
Figure 4 Shielding of adenovirus from antibody. (A-D) Electron photomicrographs of antibody-coated 10 nm gold beads bound to adenovirus and adenovirus complexes. (A) Adenovirus alone and beads coated with anti-hexon antibodies. (B) Adenovirus
Intact adenovirus is required for complex-mediated gene transfer We considered the possibility that the cationic lipid could have disrupted the virus and that we were simply transfecting adenoviral DNA. To address this possibility, we compared Ad2/␤Gal-2 alone or complexes of virus with GL-67/DOPE-PEG and we altered adenoviral proteins. Although the process of adenoviral infection is not completely understood, it is known that adenoviral proteins play important roles at several steps after binding, including endosomal disruption and transport to the nucleus. [30] [31] [32] Before forming the complex, we incubated Ad2/␤Gal-2 with neutralizing plasma and then formed the complex. Figure 5 shows that expression decreased approximately 98% compared with expression in the absence of neutralizing antibody. To control for nonspecific antibody effects, we reacted virus with nonneutralizing anti-Ad2 antibody before forming the complex; this treatment did not reduce expression. As an additional test, we heated the virus to 60°C for 30 min to disrupt viral proteins (while leaving the DNA intact) and then formed the complex. 29 After heating, there was no transgene expression. These data show that formation of a complex does not eliminate the requirement for functional viral proteins.
Administration of adenovirus complexes to immunized mice
Based on these results, we asked whether formulation of adenovirus in a complex would increase gene transfer to immunized animals. Recent work showed that factors which influence antibody neutralization of vesicular stomatitis virus (VSV) in vitro may not predict neutralization in vivo. 33 The main factor that determines antibody neutralization of VSV in vivo (with antibodies above a minimal avidity) is antibody concentration. To evaluate protection in vivo, we tested two routes of administration. We delivered the vector by intratracheal instillation to the lung and by intravenous injection. The route of administration for immunization and subsequent challenge were the same. With the different administration routes, the neutralizing activity may vary; after delivery to the lungs it may be due primarily to IgA 16, 34 and after intravenous administration it may be due primarily to IgG and IgM. 35 To avoid an immune response to the reporter, the transgene expressed by the immunizing virus was different from that used to assay expression. We analyzed transgene expression soon after administration, to minimize the effect of any cell-mediated immune response.
In an earlier study, we showed that a complex of adenovirus with a cationic lipid or PLL increased gene transfer to the nasal epithelium of mice in vivo. 21 To identify a formulation that would be effective in lung and to learn whether DOPE-PEG would alter expression in vivo, we compared the effect of administering Ad2/␤Gal-2 alone versus the virus complexed with GL-67/DOPE or GL-67/DOPE-PEG. Complexes using GL-67/DOPE-PEG proved to be the most effective, increasing expression to levels 25 times those obtained with adenovirus alone (Figure 6 ).
To immunize mice, we delivered Ad2/CMVlucif into the trachea on two occasions. Then, to measure gene transfer to the lung, we administered Ad2/␤Gal-2 alone or complexed with GL-67/DOPE-PEG. The hatched bars in Figure 7a show results obtained following delivery of adenovirus alone. Transgene was expressed in the lungs of naive animals treated with adenovirus alone. How- ever, transgene expression decreased in mice that had been immunized. The solid bars in Figure 7a show results from mice that received Ad:GL-67/DOPE-PEG. There are two main points. First, when we treated naive mice with Ad:GL-67/DOPE-PEG, pulmonary transgene expression was approximately 80-fold greater than obtained with adenovirus alone. Second, there was less transgene expression in immunized mice. Thus, immunization caused a relative decrease in transgene expression that was similar for those animals that received adenovirus alone and those that received virus complexed to GL-67/DOPE-PEG.
Figure 6 Effect of adenovirus alone and adenovirus complexes on gene transfer to mouse lung. Animals received 4 × 10 8 IU Ad2/␤Gal-2 alone or complexed with GL-67/DOPE or GL-67/DOPE-PEG. For the complexes, 200 g of GL-67/DOPE or GL-67/DOPE-PEG was complexed with 10 10 viral particles (n was 23 for adenovirus alone, 9 for Ad:GL-67/DOPE, and 11 for Ad:GL-67/DOPE-PEG). Asterisk indicates P Ͻ 0.05 compared with adenovirus alone.
Figure 7 In vivo administration of complexes to immune mice. (a) Nasal administration of complexes to immunized mice. Methods section describes immunization procedure. One week after the second immunizing
We also evaluated human ␣1-antitrypsin expression after tail vein injection of Ad2/PGKhAAT (Figure 7b) . In contrast to lung administration, where complexes produced more expression than adenovirus alone, following intravenous administration transgene expression was similar for adenovirus alone and for complexes. However, in immunized mice, neither vector generated appreciable transgene expression.
Discussion
These data show that complexing adenovirus with GL-67/DOPE-PEG partially protected it from neutralization by immune plasma. GL-67/DOPE-PEG appeared to coat the virus, forming a protective shield that prevented antibody binding.
As we previously described, the cationic component of the complex functions as a 'glue', electrostatically binding to the negatively-charged virus and to the negativelycharged cell surface. 21 For enhancing adenovirus infection, coating virus with a cationic component offers the greatest advantage for cells that are not otherwise easily infected. For example, in HeLa cells that are readily infected, the complexes produce only small improvements in gene transfer. However, in 3T3 cells that are not readily infected with a short exposure to virus, complexes significantly enhance gene transfer (Ref. 21 and Figure 3 ). Here we found a similar situation in vivo. With intravenous delivery, which readily generates transgene expression, complexes did not substantially improve expression. However in lung, where adenovirus infection is less efficient, delivering adenovirus in a complex boosted expression 25-80-fold. It is interesting that inclusion of PEG in the complex did not inhibit gene transfer; in fact with in vivo delivery to the lungs, PEG enhanced gene transfer. We speculate that in addition to increased binding with cationic lipids, 21 that the fusigenic properties of PEG 27 may have facilitated infection. Including PEG in the complex protected the virus from antibody neutralization. Complexes containing virus and GL-67 or GL-67/DOPE showed little protection. The protective effect required that DOPE-PEG be mixed, dried down, and resuspended with the GL-67 before complexing with virus; there was no effect of mixing DOPE-PEG alone with virus or of using DOPE-PEG and GL-67 which had been formulated separately. Thus, PEG plays an important role in shielding the virus. We evaluated PEG because it has been reported to decrease the interaction of macromolecules and liposomes with serum proteins and antibodies, and it is frequently used in pharmaceutical preparations to provide a hydrophilic coat and to stabilize compounds. [22] [23] [24] [25] [26] Our data indicate that PEG may play a similar role here, decreasing access of antibody to virus.
These studies leave several issues of formulation unanswered. For example, currently we have only rough estimates of the size of Ad:lipid complexes, 21 and we have not tested the size of complexes containing PEG. Moreover, the stoichiometry of virus to lipid in the final complex is not known. We often complexed 10 10 adenovirus particles, which is approximately 2.5 g of virus, with 80 g GL-67/DOPE-PEG. It seems likely that not all of the lipid-PEG will associate with virus. Thus the architecture of the complex is not known and we have not yet attempted to purify discrete particles. Studies addressing these issues might generate formulations with improved performance.
Our in vitro studies showed that complexing PEG and lipid to adenovirus partially, but not completely protected it from neutralizing antibody. However, when we tested complexes in vivo, they offered no appreciable protection in immunized mice. Despite the lack of protection in vivo, two aspects of these studies are encouraging when considering repeat administration. First, delivery of adenovirus in a complex increases gene transfer efficiency to cells and tissues that are resistant to infection. For example, in a previous study we showed that complexes were much more effective than adenovirus alone at expressing CFTR in the nasal epithelium of CF mice and correcting the CF defect. 21 In addition, here we show that complexes enhance gene transfer to lung. Use of more efficient delivery systems could allow investigators to deliver smaller doses of viral protein thereby decreasing the humoral immune response. Second, the results suggest it may be feasible to develop a system in which the virus is completely shielded from neutralizing antibodies. Such an approach could circumvent the humoral immune response in people who receive multiple adenovirus administrations or in people with pre-existing adenovirus immunity. If the use of complexes was combined with adenovirus vectors that express no viral proteins, 18-20 thereby avoiding a cellmediated immune response, it might be possible to deliver adenoviral vectors repeatedly. Such a strategy could eliminate the requirement for systemic immunosuppression with repeated administration. Our data suggest that additional studies using this and related systems with PEG warrant investigation.
Materials and methods
Vectors and vector-related reagents
We used recombinant adenovirus vectors expressing: ␤-galactosidase, Ad2/␤Gal-2; luciferase, Ad2/CMVlucif; and ␣1-antitrypsin, Ad2/PGKhAAT. These vectors were gifts from Drs Sam Wadsworth and Alan Smith (Genzyme, Framingham, MA, USA). Vectors were prepared by the University of Iowa Gene Transfer Vector Core at titers of approximately 2 × 10 10 infectious units (IU) per ml. The ratio of adenoviral particles per IU varied from 30 to 100.
The cationic lipid GL-67 was a gift from Drs Seng Cheng and David Harris (Genzyme). In some cases, GL-67 was formulated in a 1:2 molar ratio with dioleoylphosphatidylethanolamine (DOPE). DOPE-N-[poly(ethyleneglycol)5000] (DOPE-PEG) and DOPE-N-PEG-2000 were purchased from Avanti Polar Lipids (Alabaster, AL, USA). GL-67/DOPE-PEG was formulated at a w/w ratio of 1/1 based on our unpublished optimization experiments.
Preparation of complexes of adenovirus and polycations
Complexes of cationic components and adenovirus particles were formed by diluting the cationic component and the adenoviral components in Eagle's MEM (Gibco, Gaithersburg, MD, USA). The cationic component was added to the viral particles, mixed by inversion or gentle pipette tip aspiration, and allowed to incubate for 15 min at room temperature before exposure to plasma and application to cells. We refer to adenovirus:cationic molecule complexes based on the total weight of the cationic components (including noncationic components such as DOPE-PEG) per 10 10 adenoviral particles. Ratios of cationic components to adenoviral particles and volumes are described in the text and Figure legends.
Cell culture NIH-3T3 cells were cultured on 96-well plates in DMEM (high glucose) supplemented with 10% fetal calf serum (FCS; Sigma Chemical, St Louis, MO, USA) and 100 U/ml penicillin and 100 g/ml streptomycin. HeLa cells were cultured on 96-well plates in Eagle's MEM supplemented with 10% FCS, 10 mm nonessential amino acids (Sigma), 100 U/ml penicillin and 100 g/ml streptomycin. Cells were seeded at 2 × 10 4 cells per cm 2 and studied 1-2 days later.
When evaluating expression by cells in vitro, adenovirus and adenovirus complexes were prepared and then combined with immune or nonimmune plasma for 30 min at room temperature. The preparation was then applied to cells at a multiplicity of infection (MOI) of 50-100. Cells were studied in triplicate in all experiments. After a 20-30 min incubation, vector and plasma were removed by washing twice with PBS. Cells were harvested 24 h later to measure ␤-galactosidase activity using the Galactolite assay (Tropix, Bedford, MA, USA); values (in light units, LU) were divided by milligrams of total protein.
Production and evaluations of immunized rat plasma Two 3-month-old Sprague-Dawley rats from HarlanSprague Laboratories (Indianapolis, IN, USA) were injected in the femoral vein with 10 10 IU of Ad2/CFTR-8. Three weeks later, the rats received a second dose of 10 9 IU of Ad2/CFTR-8. Animals were killed 1 week later, blood was collected, pooled and plasma was isolated by centrifugation. In a few experiments immune plasma was heated (65°C for 30 min); the results were similar and are combined. Figure 8 shows a Western blot with immunized rat plasma and adenoviral proteins. The immune plasma recognized multiple viral proteins, including hexon, fiber, penton base and other minor capsid proteins. As shown in the Figures, the antibodies were neutralizing. As a control for immune plasma, we used nonimmune plasma. For some experiments, we also used non-neutralizing, anti-hexon antibodies (MAB8052; Chemicon, Temecula, CA, USA).
To evaluate the interaction of antibody with adenovirus, 3 g of biotinylated anti-hexon goat antibody (Virostat, Portland, ME, USA) was incubated on a rotating mixer with Ad2/␤Gal-2 alone or in complexes for 1 h at room temperature. We then added 40 l of magnetic beads (Dynal, Lake Success, NY, USA) and incubated on the mixer for another hour. Beads were then precipitated with a magnet and washed twice with phosphatebuffered saline (PBS). Precipitated beads were resuspended in 500 l 1% SDS and freeze-thawed three times. This solution was centrifuged at 5800 g for 1 min to spin down debris. The supernatant was blotted on to a nitrocellulose membrane pre-wet with 5 × SSC. The membrane was exposed to UV light for 2 min (UV Stratalinker; Stratagene, La Jolla, CA, USA) to link the DNA to the membrane. The blot was then probed with 32 P-labeled pCMV-␤Gal plasmid and analyzed by autoradiography. Quantification was performed using a Molecular Dynamics Storm System (Sunnyvale, CA, USA).
Electron microscopy
To label adenovirus with gold beads, polyclonal goat anti-hexon antibody (Virostat) and nonspecific antibody were dialyzed in 5 mm NaCl and 5 mm Na 2 HPO 4 pH 9 for 12 h at 4°C. Antibody (25 g) in 1.1 ml of reaction buffer was coupled to 300 g of 10 nm gold beads (EMS, Fort Washington, PA, USA) for 2 min at room temperature. Bovine serum albumin (10%, 110 l) was added to prevent aggregation. The mixture was spun at 50 000 g for 30 min at 4°C. The fluffy pellet was resuspended and the centrifugation repeated. As a positive control for antibody function, the preparation was found to bind to adenoviral proteins on dot blots. Adenovirus and the various complexes were placed on the nickel-coated grids for 20 min at room temperature. Grids were then blocked with 3% BSA in PBS for 30 min. The antibody-coated gold beads were placed on the grids at room temperature. After 1 h, grids were rinsed six times with PBS and once with water. Grids were then stained with uranyl acetate and evaluated by transmission electron microscopy.
Studies in mice
For in vivo analysis, we used 6-8-week-old C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME, USA). For lung gene transfer, we evaluated expression of ␤-galactosidase. During immunization, animals were anesthetized with methofane and Ad2/CMVlucif was delivered in 75 l by nasal instillation. Animals received 10 10 particles on day −28 and 3 × 10 10 on day −7. Then on day 0, animals received 4 × 10 8 IU Ad2/␤Gal-2 in two 75 l instillations delivered 15-30 min apart. Three days after vector administration, animals were killed and the lungs were removed for determination of ␤-galactosidase activity and protein. For intravenous administration, we evaluated expression of ␣1-antitrypsin. We immunized mice by injecting 5 × 10 8 IU of Ad2/CFTR-8 into the tail vein on days −27 and −10. The control group was not immunized. On day 0, tail veins were injected with 10 9 IU of Ad2/PGKhAAT. On the indicated days after challenge, plasma was assayed for human ␣1-antitrypsin.
